Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice President for Research and Development in Tel Aviv University, the biggest university in Israel. From 2016-2020, he was the Chair of Tel Aviv University Cancer Biology Research Center, which includes 17 affiliated hospitals and from 2017, he is the Founding and Managing Director of the SPARK program, Center for Translational Medicine at TAU.
Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) as drug discovery tools in immune cells. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA to cells to induce therapeutic gene expression of desired proteins that has enormous implications in cancer, inflammation and infection diseases and the first to show systemic, cell specific and high efficiency therapeutic genome editing in cancer. Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies. In addition, based on his work, five spin-off companies were generated aiming to bring innovative personalized medicine into clinical practice. Prof. Peer is a scientific advisory board member in more than 15 companies and on the scientific advisory board of more than 20 journals. He is a past President of the Israeli Chapter of the Controlled Release Society, and a Member of the Board of the Israel Young Academy of Science.